Pharma M&A Counsel in 2026: Corporate Lawyers on 23.4% of Deals

A general counsel or business development head at a drug or biotech company who is choosing pharma M&A law firms should start with how much of the sector's legal work is M&A at all. Sartori & Partners data show that corporate and M&A lawyers worked on 23.4% of pharma and biotech deals in the 12 months to October 2026, 765 deals in all. In technology the same practice appeared on 47.8% of deals, 2.0 times the pharma share. Across every sector the practice's share was 23.3%, so pharma sits at the market's level and technology is the outlier. For a buyer, that sets the terms of a search: the corporate partners who would run an acquisition or a licensing deal spend their year on many sectors, and the sector's own volume runs through capital markets lawyers first.

The gap between the two sectors is 24.4 points. Technology companies buy and sell businesses as a routine legal event; drug developers mostly raise money. Capital markets lawyers worked on 53.1% of pharma and biotech deals and on 24.0% of technology deals, the mirror image of the corporate figures. Deal types tell the same story: M&A transactions were 17.5% of the sector's deals, against 30.0% in technology and 19.3% across the whole deal record. One deal can carry lawyers from several practices, so practice shares overlap and are never added.

For a pharma buyer, the practical point is that a corporate team's sector record is a small slice of its total. The 765 pharma and biotech deals with corporate lawyers on them sit inside a sector total of 3,276. When a firm pitches its M&A credentials, ask for the life sciences transactions its proposed partners closed in the past 12 months, separated from its offerings and from its deals in other industries.

Seen from the bench's side, the picture is a shared resource. In the Sartori & Partners deal record, the corporate and M&A practice worked on 11,230 deals over 12 months, and pharma and biotech was the client sector on 765 of them, or 6.8%. Technology was the client sector on 14.0%, 2.1 times as much. Pharma's share of the bench matches its share of all dated deals, 6.8%: the sector draws on corporate lawyers in line with its size. Technology was the client sector on 6.8% of all deals but on 14.0% of corporate work.

Pharma still ranks second on that list, ahead of power and renewables at 4.9% and banks and financial institutions at 4.0%. So the sector is a large client group for corporate lawyers, but one among many: the team that closes your acquisition also serves software, energy and finance clients. At the pitch, ask whether the partners who would run your deal have closed life sciences transactions in the past 12 months, and whether regulatory and intellectual property diligence sits in the same team or is pulled in from other groups.

Demand from the sector is growing faster than the bench that serves it. Pharma and biotech deals rose 14.5% year on year, from 2,880 in the 12 months to September 2025 to 3,298 in the 12 months to September 2026. Corporate and M&A deals across all sectors rose 9.5%, from 10,198 to 11,170, and the whole deal record rose 10.6%. Technology deal flow held flat (+4.6%) over the same windows, from 3,136 to 3,279.

The sector count covers every pharma and biotech matter, offerings and disputes included, so it does not isolate pharma M&A; no trend is published for that pair. Read together, Sartori & Partners figures still show the sector's legal work expanding faster than the corporate practice's own workload. When a sector's demand outpaces the bench, partner time becomes the constraint. Engage M&A counsel when a process is being planned, not after a term sheet is signed, and ask how many live life sciences deals the proposed team is already carrying.

No firm list exists for pharma M&A alone. The list below ranks advisers on all pharma and biotech deals, capital markets and disputes included, so it measures sector depth rather than M&A depth. Cooley and Goodwin Procter share the top band, at 251-400 deals each over 12 months, followed by Latham & Watkins and Wilson Sonsini Goodrich & Rosati in the 151-250 band.

Checked name by name against the corporate and M&A top 10 for all sectors, five firms appear on both lists: Cooley (7th on corporate work), Goodwin Procter (4th), Latham & Watkins (1st), Wilson Sonsini Goodrich & Rosati (3rd) and Gibson, Dunn & Crutcher (8th). The other five sector firms, Ropes & Gray, Davis Polk & Wardwell, Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, Sidley Austin and Covington & Burling, are not in the corporate top 10, which carries Kirkland & Ellis, DLA Piper, CMS, White & Case and Fenwick & West instead.

A sector-first firm brings life sciences diligence and regulatory reach; a corporate-first firm brings deal volume across industries. The five firms on both lists offer both, and a shortlist for a sizable acquisition can start there. A firm that ranks on the sector list alone deserves a test on the M&A partners it would field, since its sector rank rests on all its pharma and biotech work, offerings included.

Where the work is done shapes who staffs your deal. 45.9% of pharma and biotech deals were handled with lawyers in New York, against 38.7% of technology deals. Boston shows the widest gap of the cities on both lists: 25.5% of the sector's deals were handled with lawyers there, against 10.1% of technology's. Washington, DC follows at 25.0% against 19.6%, and San Diego appears on the sector's list at 13.5%. The Bay Area runs the other way: San Francisco, Palo Alto and Silicon Valley each carry a lower share for pharma than for technology. One deal counts in every city whose lawyers worked on it, so these shares are never added.

For a pharma buyer, Boston and Washington teams are part of the sector's normal staffing, not a regional extra. Ask where the M&A partners on your deal sit and where the regulatory and intellectual property lawyers sit. A team spread across New York, Boston and Washington is common in this sector; what matters is that one partner owns the deal and the others answer to that partner.

Hire for the work you actually have. Corporate and M&A lawyers sit on 23.4% of the sector's deals, against 47.8% in technology, so any corporate team's life sciences record will be thinner than its overall record: ask for the sector deals, not the total. Expect to share the bench. Pharma and biotech was the client sector on 6.8% of the corporate practice's deals, and the partners you want also serve the technology clients on 14.0% of them. Book early: sector deals rose 14.5% against 9.5% for corporate work, so the busiest partners fill their calendars first. Start the shortlist with the five firms on both lists, then test one sector-first name from the rest of the pharma list on the M&A partners it would field. Staff by city: with 25.5% of sector deals handled with lawyers in Boston, a team with no Boston lawyers is a choice that needs a reason.